{"prompt": "['2016N298481_0', 'CONFIDENTIAL', '205270', 'Contraception Guidance', 'Women of childbearing potential are eligible to participate if they agree to use a highly', 'effective method of contraception consistently and correctly as described in Table 9.', 'Table 9', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulation', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulation', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', 'NOTES:', 'a. Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent', 'with local regulations regarding the use of contraceptive methods for participants in clinical studies.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'urine FRP test.', '90']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Additional pregnancy testing should be performed per SoA (Section 2) during the', 'treatment period and 30 days after the last dose of study treatment and as required', 'locally', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected.', 'Collection of Pregnancy Information', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within 2', \"weeks of learning of a participant's pregnancy.\", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Section 12.3 (Appendix 3). While the investigator is not obligated to', 'actively seek this information in former study participants, he or she may learn of an', 'SAE through spontaneous reporting.', 'Any female participant who becomes pregnant while participating must', 'permanently discontinue randomized treatment. Participants will be asked to attend', 'an Early Treatment Discontinuation visit and expected to attend study visits', 'through the End of Study visit, according to the study visit schedule, unless consent', 'is actively withdrawn.', '91']['2016N298481_02', 'CONFIDENTIAL', '205270', '12.5.', 'Appendix 5: Genetics', 'USE/ANALYSIS OF DNA', \"Genetic variation may impact a participant's response to therapy, susceptibility,\", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis', 'DNA samples will be used for research related to daprodustat or anemia associated', 'with CKD and related diseases. They may also be used to develop tests/assays', '(including diagnostic tests) related to daprodustat (or study treatments of this drug', 'class), and anemia associated with CKD. Genetic research may consist of the', 'analysis of one or more candidate genes or the analysis of genetic markers', 'throughout the genome.', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'DNA samples will be analyzed initially using genome-wide genotyping and', 'performing genome-wide and candidate gene analysis of efficacy measures.', 'Additional analyses may be conducted if it is hypothesized that this may help further', 'understand the clinical data, such as investigating PK and/or safety endpoints as well', 'as sequencing of the DNA.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to daprodustat or study treatments of this class. The results', 'of genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'GSK will store the DNA samples in a secure storage space with adequate measures', 'to protect confidentiality.', 'The samples will be retained while research on daprodustat (or study treatments of', 'this class) or anemia associated with CKD continues but no longer than 15 years', 'after the last subject last visit or other period as per local requirements.', 'Study Population', 'Any subject who is randomized in the study can participate in genetic research. Any', 'subject who has received an allogeneic bone marrow transplant must be excluded from', 'the genetic research.', 'Study Assessments and Procedures', 'A key component of successful genetic research is the collection of samples during', 'clinical studies. Collection of samples, even when no a priori hypothesis has been', 'identified, may enable future genetic analyses to be conducted to help understand', 'variability in disease and medicine response.', '92']\n\n###\n\n", "completion": "END"}